journal article·2025-07

Advancing Cellular‐Specific Delivery: Machine Learning Insights into Lipid Nanoparticles Design and Cellular Tropism

Belal I. Hanafy, Michael J. Munson, Ramesh Soundararajan, Sara Pereira, Audrey Gallud, Sajib Md Sanaullah, Gianluca Carlesso, Mariarosa Mazza

Advanced Healthcare Materials· Volume 14· Issue 18
Publisher page

Abstract

Abstract Lipid nanoparticles (LNPs) have gained significant attention as effective nucleic acid delivery vehicles. Despite their success, LNPs are predominantly liver‐targeted which limits their broader application. To expand the therapeutic potential of LNPs, this work implements a data‐driven approach that combines design of experiments (DoE), high throughput screening (HTS), and machine learning (ML) to tailor LNP formulations for preferential immune cell targeting. This methodology involves the generation of 180 LNP formulations, with varying lipid molar ratios and lipid chemistries, to explore a diverse design space. This work aims to identify LNP properties that enhance immune cell specificity while reducing hepatic uptake. The in vitro screening of these LNPs provided a rich dataset for ML analysis, leading to the identification of promising candidates with improved immune cellular selectivity profiles. These findings are validated in vivo where it is demonstrated that selected LNPs achieved preferential spleen expression with a successful redirection of LNP tropism beyond hepatic cells. This workflow highlights the importance of tailoring LNP compositions for the development of LNPs with selective cellular tropism.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · SARS-CoV-2 and COVID-19 Research · Immunotherapy and Immune Responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Advanced Drug Delivery, Pharmaceutical Sciences Biopharmaceuticals R&D AstraZeneca Cambridge CB2 0AA United Kingdom

Advanced Drug Delivery Pharmaceutical Sciences Biopharmaceuticals R&D AstraZeneca Gothenburg 431 83 Sweden

Early ICC Discovery R&D Oncology AstraZeneca Gaithersburg MD 20878 USA

Funding

AstraZeneca

References (44)

Show source-provided references
1. 10.1056/NEJMoa203457710.1056/NEJMoa2034577 ↗
2. 10.1056/NEJMoa203538910.1056/NEJMoa2035389 ↗
3. 10.1039/D3NH00145H10.1039/D3NH00145H ↗
4. 10.1016/j.jconrel.2012.12.02910.1016/j.jconrel.2012.12.029 ↗
5. 10.1038/sj.gt.330236410.1038/sj.gt.3302364 ↗
6. 10.1038/nrg106610.1038/nrg1066 ↗
7. 10.1016/j.jconrel.2023.03.01110.1016/j.jconrel.2023.03.011 ↗
8. 10.1021/acsabm.0c0146310.1021/acsabm.0c01463 ↗
9. 10.1021/ar700233610.1021/ar7002336 ↗
10. 10.1002/anie.20120326310.1002/anie.201203263 ↗
11. 10.1038/ncomms527710.1038/ncomms5277 ↗
12. 10.1074/jbc.M30864320010.1074/jbc.M308643200 ↗
13. 10.1038/mt.2010.8510.1038/mt.2010.85 ↗
14. 10.1021/acs.molpharmaceut.2c0003210.1021/acs.molpharmaceut.2c00032 ↗
15. 10.3390/biom1202022310.3390/biom12020223 ↗
16. 10.1016/j.ijpharm.2023.12301210.1016/j.ijpharm.2023.123012 ↗
17. 10.1016/j.apsb.2021.11.02110.1016/j.apsb.2021.11.021 ↗
18. 10.3390/pharmaceutics1211104210.3390/pharmaceutics12111042 ↗
19. 10.1021/acs.nanolett.5b0249710.1021/acs.nanolett.5b02497 ↗
20. 10.1016/j.biomaterials.2023.12215810.1016/j.biomaterials.2023.122158 ↗
21. 10.1021/acsnano.9b0277410.1021/acsnano.9b02774 ↗
22. 10.1016/j.cej.2022.13631010.1016/j.cej.2022.136310 ↗
23. 10.1016/j.addr.2023.11510810.1016/j.addr.2023.115108 ↗
24. 10.1021/acsnano.4c0761510.1021/acsnano.4c07615 ↗
25. 10.1021/acsami.2c0662710.1021/acsami.2c06627 ↗
26. 10.1038/s41598-023-43689-410.1038/s41598-023-43689-4 ↗
27. 10.1002/smtd.20220169510.1002/smtd.202201695 ↗
28. 10.2217/nnm-2020-046110.2217/nnm-2020-0461 ↗
29. 10.1002/adma.20221142010.1002/adma.202211420 ↗
30. 10.1016/j.jconrel.2016.05.05910.1016/j.jconrel.2016.05.059 ↗
31. 10.1016/j.jconrel.2022.05.02010.1016/j.jconrel.2022.05.020 ↗
32. 10.1038/s41596-022-00755-x10.1038/s41596-022-00755-x ↗
33. 10.1073/pnas.210925611810.1073/pnas.2109256118 ↗
34. 10.1073/pnas.172054211510.1073/pnas.1720542115 ↗
35. 10.1038/s41565-019-0591-y10.1038/s41565-019-0591-y ↗
36. 10.3389/fphys.2021.73557310.3389/fphys.2021.735573 ↗
37. 10.1186/s12951-024-02630-110.1186/s12951-024-02630-1 ↗
38. 10.1002/smll.20230437810.1002/smll.202304378 ↗
39. 10.1089/nat.2018.073410.1089/nat.2018.0734 ↗
40. J.Grayson S.Gardner M.Stephens Building Better Models with JMP Pro SAS Institute Cary North Carolina 2015.
41. C. M.Gotwalt JMP Neural Network Methodology SAS Institute Cary North Carolina 2011.
42. JMP Assess Variable Importance JMP 2024 JMP.com.
43. Gallud A. · 2024
44. 10.1021/la204833h10.1021/la204833h ↗